GeneMind Biosciences Company Limited (GeneMind) is a technology company focused on genetic sequencing platforms and multi-omics technologies. The company develops sequencing systems and related consumables for life science research and industrial applications.
Its product portfolio includes the GenoCare 1600, FASTASeq S, FASTASeq 300, GenoLab M, SURFSeq 5000 and SURFSeq Q sequencing platforms, covering low- to ultra-high-throughput workflows. The platforms are designed to support flexible and scalable workflows and are compatible with diverse research and partner-supported applications.
Guided by its mission "Explore life's mystery for better healthcare", GeneMind pursues technological innovation and adheres to stringent quality standards, empowering both academic and clinical customers to advance life science.
+
%
+
+
+
+
Simple
Communicate directly and candidly
Pragmatic
Innovate with rigorous work
Enterprising
Pursue lifelong learning relentlessly
Collaboration
Collaborate across disciplines
July
GenoCare single-molecule gene sequencer, NIPT, PGT-A test kits and other five products received the EU CE certification.
Completed 140 million of B-round financing. Expanded sequencing applications.
Genemind released new sequencing platform–GenoLab in special product launch event.
The production base of the GenoLab M series high-throughput gene sequencer was officially put into operation, further improving the overall production and delivery capacity and speed.
November
Following the approval to establish the Guangdong Provincial Academician Workstation, it was awarded the license of the Shenzhen Municipal Academician (Expert) Workstation and became a gene sequencer enterprise with provincial and municipal level academician workstations.
Launched the Tb‑scale benchtop genetic sequencer SURFSeq 5000, completing full‑coverage product portfolio spanning from Gb‑scale to Tb‑scale throughput.
GenoLab M Dx obtained the Class III Medical Device Certificate from NMPA.
SURFSeq Q launched — world’s highest daily data output per single sequencer.
Selected as a key National‑level SRDI "Little Giant" Enterprise by MIIT.
FASTASeq 300 Dx received the Class‑III Medical Device Registration Certificate from NMPA.
Launched FASTASeq S, the world’s fastest sequencer.
Unveiled key deliverables of the Ministry of Science and Technology special project: NanaLyzer 96 Nucleic Acid Fragment Analyzer; launched CMS Sequencing Technology, enabling global bias‑free Q50 detection.
GeneMind SURFSeq™ 5000 Dx has obtained the NMPA Class III Medical Device Registration Certificate.
GeneMind Biosciences has secured nearly RMB 600 million in Series D financing, which will accelerate its innovation in omics technologies and global market expansion.
